Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with mFOLFIRI as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma
NCT01486992Phase 2Unknown
- Sponsor
- Peking University
- Start
- Nov 2011
- Primary completion
- Nov 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Primary endpoints: Overall Survival at 2 years and Adverse Events at 2 weeks. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01486992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486992.